imatinib mesylate

Phase 2/3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Malignant Peripheral Nerve Sheath Tumors

Conditions

Malignant Peripheral Nerve Sheath Tumors

Trial Timeline

May 1, 2006 → —

NCT ID

NCT00427583

About imatinib mesylate

imatinib mesylate is a phase 2/3 stage product being developed by Novartis for Malignant Peripheral Nerve Sheath Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT00427583. Target conditions include Malignant Peripheral Nerve Sheath Tumors.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01742299	Approved	Active	Mar 26, 2013	Apr 21, 2033	GIST and CML
NCT00867113	Phase 2	Completed	Jul 22, 2009	Dec 20, 2016	Gastrointestinal Stromal Tumor (GIST)
NCT00732784	Phase 1	Completed	Nov 1, 2008	Dec 1, 2012	Healthy
NCT01172548	Phase 2	Completed	Aug 1, 2008	Mar 1, 2014	Gastrointestinal Stromal Tumors
NCT01483014	Phase 2	Completed	Jun 1, 2008	Jan 1, 2012	Gastrointestinal Stromal Tumors
NCT00684411	Phase 2	Completed	Jun 1, 2008	Oct 1, 2013	T Cell Non-Hodgkin Lymphoma
NCT01545427	Phase 2	Terminated	Apr 1, 2008	Dec 1, 2008	Scleroderma
NCT00479934	Phase 2	Completed	Dec 1, 2007	Dec 1, 2010	Scleroderma, Localized
NCT00677092	Phase 2	Completed	Dec 1, 2007	Jul 1, 2009	Nephrogenic Systemic Fibrosis
NCT00555581	Phase 2	Completed	Aug 1, 2007	Dec 1, 2011	Systemic Sclerosis
NCT00510354	Approved	Completed	Oct 1, 2006	Nov 1, 2012	Progressive Gastrointestinal Stromal Tumor
NCT00427583	Phase 2/3	Terminated	May 1, 2006	—	Malignant Peripheral Nerve Sheath Tumors
NCT00124748	Phase 3	Terminated	Jun 1, 2005	Nov 1, 2010	Leukemia, Myeloid, Chronic Phase
NCT00171899	Approved	Completed	Apr 1, 2005	Jun 1, 2007	Chronic Myelogenous Leukemia
NCT00171912	Phase 2	Completed	Sep 1, 2004	Jan 1, 2012	Hypereosinophilic Syndrome
NCT00171977	Approved	Completed	Jul 1, 2004	—	Gastrointestinal Stromal Tumors
NCT00171938	Phase 2	Terminated	Apr 1, 2004	Jun 1, 2006	Glioblastoma
NCT00154349	Phase 2	Completed	Oct 1, 2003	Feb 1, 2007	Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
NCT00237172	Phase 2	Completed	Sep 1, 2002	—	Gastrointestinal Stromal Tumors
NCT00171860	Phase 2	Terminated	Sep 1, 2002	—	Hypereosinophilic Syndrome

Competing Products

20 competing products in Malignant Peripheral Nerve Sheath Tumors

See all competitors

Product	Company	Stage	Hype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + Bevacizumab	CSPC Pharmaceutical Group Limited	Phase 1/2	40
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	52
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	33
Patritumab Deruxtecan	Daiichi Sankyo	Phase 1/2	41
Tivantinib + FOLFOX	Daiichi Sankyo	Phase 1/2	41
DS-1123	Daiichi Sankyo	Phase 1	33
DS-8201a	Daiichi Sankyo	Phase 1	33
DS-5573a	Daiichi Sankyo	Phase 1	33
DS-6051b	Daiichi Sankyo	Phase 1	33
U3-1565	Daiichi Sankyo	Phase 1	33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue Medications	Daiichi Sankyo	Phase 1/2	41
DS-3201b + DS-3201b	Daiichi Sankyo	Phase 1	33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kg	Daiichi Sankyo	Phase 1	33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	41
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	52
CP-461	Astellas Pharma	Phase 2	52
enfortumab vedotin	Astellas Pharma	Phase 1	33
LNF1901 Monoclonal Antibody Injection	Sun Pharmaceutical	Phase 1	33
Perampanel + Standard of Care	Eisai	Phase 1/2	41
Pembrolizumab + Lenvatinib + Placebo for lenvatinib	Eisai	Phase 3	77

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved